Antigenics Reports Positive Trial Results


Shares of Antigenics Inc. (Nasdaq: AGEN) soared $1.25 to $2.78 after the drug research company reported positive results for its treatment of patients with kidney cancer.

About this Entry

This page contains a single entry by published on June 3, 2009 10:24 AM.

Cardinal Health Increases Dividend was the previous entry in this blog.

Valero Energy Lowers Guidance is the next entry in this blog.

Find recent content on the main index or look in the archives to find all content.

Powered by Movable Type 5.12